Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2002
09/26/2002US20020136726 Method for selectively delivering agent to arterial smooth muscle cells in mammal comprising administering agent and substance which selectively binds arterial smooth muscle cell-specific surface molecule selected from ephrin family
09/26/2002US20020136723 Administering methotrexate and an anti-tumor necrosis factor antibody or fragment thereof; rheumatoid arthritis, Crohn's disease, acute and chronic immune diseases
09/26/2002US20020136720 Methods of using IMXP-888 and IMXP-888 antagonists
09/26/2002US20020136701 Applying to area of body having ectoparasites a composition comprising non-volatile surfactants, polar organic compounds, non-volatile fatty alcohols, and non-volatile fatty esters, for a time sufficient to trigger immersion reflex, drying
09/26/2002US20020136697 4-hydroxyisothiazole compounds
09/26/2002US20020136689 Antibody which specifically binds to prostate stem cell antigen on surface of carcinoma cells and is internalized within carcinoma cells to which it binds
09/26/2002US20020135085 Production scale method of forming microparticles
09/26/2002DE10114305A1 Reducing sebum production using cosmetic or dermatological preparations containing isoflavones, useful for e.g. eliminating comedones or treating greasy hair or dandruff
09/26/2002DE10113402A1 New N,N'-bis-(Aminocarbonyl)-hydrazine derivatives are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, apoplexy, restenosis or tumors
09/26/2002DE10113366A1 Medicament for treating inflammatory or obstructive respiratory diseases, e.g. asthma or chronic obstructive pulmonary disease, containing synergistic combination of anticholinergic agent and endothelin antagonist
09/26/2002DE10112771A1 New 3-acylamino-3-phenyl-propionic acid derivatives, are integrin inhibitors useful e.g. for treating thrombosis, cardiac infarction, angina pectoris, tumor diseases, inflammation, osteoporosis or infections
09/26/2002DE10112041A1 p-Thienylbenzyl-Amide als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate p-thienylbenzyl amides as agonists of angiotensin- (1-7) receptors, processes for their preparation, their use and pharmaceutical compositions containing them
09/26/2002DE10110391A1 Hochflexibles Nikotin transdermales therapeutisches System mit Nikotin als Wirkstoff Highly flexible nicotine transdermal therapeutic system with nicotine as a drug
09/26/2002CA2758923A1 Use of tramadol to delay ejaculation
09/26/2002CA2448795A1 Amino acid derivatives of triptolide compounds as immune modulators and anticancer agent
09/26/2002CA2445374A1 Process for producing lactic acid oligomer
09/26/2002CA2444526A1 Metalloproteinase inhibitors
09/26/2002CA2442717A1 Methods for restoring cognitive function following systemic stress
09/26/2002CA2442268A1 Benzimidazol derivatives modulate chemokine receptors
09/26/2002CA2442000A1 Pharmaceutical composition for the treatment of diabetes comprising a 5-phenoxyalkal-2,4-thiazolidinedione derivative and a compound that stimulates insulin secretion
09/26/2002CA2441822A1 Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor
09/26/2002CA2441616A1 Composition comprising cocoa and a dopamine d2 receptor agonist
09/26/2002CA2441563A1 Allosteric adenosine receptor modulators
09/26/2002CA2441536A1 Polybutene containing chewing gum and confection
09/26/2002CA2441503A1 Method for cleaving human growth hormone gh
09/26/2002CA2441428A1 Highly purified and crystalline form of harringtonine
09/26/2002CA2441427A1 Biurethane derivatives
09/26/2002CA2441425A1 Antipruritics
09/26/2002CA2441291A1 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
09/26/2002CA2441289A1 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
09/26/2002CA2441202A1 Chemical compounds
09/26/2002CA2441162A1 Pharmaceutical composition comprising, as an active ingredient, triazaspiro[5.5]undecane derivative
09/26/2002CA2441155A1 Methods of treating respiratory conditions
09/26/2002CA2441152A1 Hormone replacement therapy
09/26/2002CA2441111A1 Method for targeting chemical compounds to cells and pharmaceutical compositions used therein
09/26/2002CA2441064A1 Controlled release sulfonylurea formulation
09/26/2002CA2441016A1 Taurine compounds
09/26/2002CA2440954A1 Phenyl derivatives 3
09/26/2002CA2440844A1 Two-phase processing of thermosensitive polymers for use as biomaterials
09/26/2002CA2440687A1 Dermatological preparations
09/26/2002CA2440632A1 Metalloproteinase inhibitors
09/26/2002CA2440631A1 Metalloproteinase inhibitors
09/26/2002CA2440482A1 Tryptase-inhibitors
09/26/2002CA2440480A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
09/26/2002CA2440475A1 Metalloproteinase inhibitors
09/26/2002CA2440391A1 Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives
09/26/2002CA2440264A1 Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient
09/26/2002CA2440261A1 Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
09/26/2002CA2440106A1 Substituted benzopyranones as telomerase inhibitors
09/26/2002CA2440002A1 Pyrrolidine ester derivatives with oxytocin modulating activity
09/26/2002CA2439952A1 Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors
09/26/2002CA2439757A1 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
09/26/2002CA2439528A1 Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors
09/26/2002CA2436911A1 Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors
09/26/2002CA2435847A1 Aniline derivatives useful as phosphodiesterase 4 inhibitors
09/26/2002CA2435825A1 New composition
09/26/2002CA2435664A1 Ncc2705-the genome of a bifidobacterium
09/26/2002CA2434030A1 Stabilized formulation of selective ligands of retinoic acid gamma-receptors
09/26/2002CA2430619A1 Farnesyltransferase inhibitors
09/26/2002CA2404701A1 Triazole compounds having amide linkage
09/26/2002CA2404581A1 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication
09/26/2002CA2404422A1 Preparations for preventing bile acid diarrhea
09/26/2002CA2404381A1 Oily compositions containing highly fat-soluble drugs
09/26/2002CA2403903A1 Angiogenesis inhibitors
09/25/2002WO2001074354A1 DIURETICS CONTAINING η-TOCOTRIENOL
09/25/2002EP1243652A2 Glial derived neurotrophic factor
09/25/2002EP1243650A2 Process for constructing a cdna library, and a polypeptide and dna coding for the same
09/25/2002EP1243597A2 Receptors for human interleukin-12
09/25/2002EP1243586A1 Phloridzin-rich phenolic fraction and its use as cosmetic, food or nutritional agent
09/25/2002EP1243583A1 Heterocyclic compounds having sulfonamide groups
09/25/2002EP1243582A1 Quinoline and quinazoline derivatives and drugs containing the same
09/25/2002EP1243581A1 Pyridinium compounds useful for the treatment of AGE-related diseases
09/25/2002EP1243290A2 Modulation of gene expression by combination therapy
09/25/2002EP1243276A1 Elongated and multiple spacers containing activatible prodrugs
09/25/2002EP1243273A1 Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
09/25/2002EP1243272A2 Crystalline amifostine compositions and methods for the preparation and use of same
09/25/2002EP1243271A1 Nasal drops containing fused pyridazine derivatives
09/25/2002EP1243270A1 Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
09/25/2002EP1243269A2 Opioid formulations having extended controlled release
09/25/2002EP1243268A1 Medicinal composition
09/25/2002EP1243267A2 Amoxycillin and clavulanate containing pharmaceutical formulation
09/25/2002EP1243266A1 Solid preparations for oral use
09/25/2002EP1243264A2 Inhibition of nitric oxide production by retinoic acid
09/25/2002EP1243263A1 Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
09/25/2002EP1243262A1 Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
09/25/2002EP1243261A1 Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia
09/25/2002EP1243259A1 Sustained release preparation comprising one or more antibiotics and polymers
09/25/2002EP1243258A1 Production of a preparation comprising one or more antibiotics
09/25/2002EP1243257A1 Sustained release preparation comprising one or more antibiotics
09/25/2002EP1243255A2 Method of preparation of antibiotic compositions
09/25/2002EP1243252A1 Skin composition containing fibres and ubiquinones
09/25/2002EP1242609A2 Novel colloid synthetic vectors for gene therapy
09/25/2002EP1242608A2 Method of achieving persistent transgene expression
09/25/2002EP1242590A2 Human lyases and associated proteins
09/25/2002EP1242587A1 A NOVEL ISOFORM OF HUMAN cAMP-DEPENDENT PROTEIN KINASE, C ALPHA-s, LOCALIZES TO SPERM MIDPIECE AND THE USE THEREOF
09/25/2002EP1242585A1 IDENTIFICATION OF NOVEL SPLICE VARIANTS OF THE HUMAN CATALYTIC SUBUNIT C BETA OF cAMP-DEPENDENT PROTEIN KINASE AND THE USE THEREOF
09/25/2002EP1242449A1 Modified adenovirus fibre and uses
09/25/2002EP1242445A1 14,15-cyclopropanosteroids of the 19-norandrostane series, method for producing said compounds and pharmaceutical preparation containing said compounds
09/25/2002EP1242438A1 Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
09/25/2002EP1242437A2 Novel stromelysin inhibitors